Employers Encourage Mental Health
More companies are trying to destigmatize mental illness and encourage workers to take off for their own mental health. According to The Wall Street Journal, initiatives offering free counseling, access to mental health professionals at the office, and flexible work arrangements are popping up at some big employers. Unfortunately, most workers with a mental illness keep it a secret at work, with a large majority of people not telling employers that they have depression even though the law protects them from losing their jobs.
Hedging Against Healthcare Stocks
Hedge funds are selling shares in healthcare stocks even as the stock market continues to climb. Since the beginning of the current quarter, healthcare stocks have underperformed, reported Reuters. The quarter began in July 1, shortly after Senate Republicans delayed a vote on a healthcare bill and ultimately did not pass a plan to repeal and replace the Affordable Care Act. Uncertainty over the future of healthcare may have dimmed investors’ enthusiasm for the sector.
Merck CEO Quits Presidential Council
A total of 3 CEOs left the presidential business council on Monday. The departures were kicked off by an announcement from Kenneth C. Frazier, the CEO of Merck, that he was leaving the business council, according to The New York Times. By the end of the day, Kevin Plank of Under Armor and Brian Krzanich of Intel had followed suit. The president responded to Frazier’s decision by tweeting at him that he should spend more time lowering “ripoff drug prices.”
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More